Revvity, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RVTY research report →
Companywww.revvity.com
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics.
- CEO
- Prahlad R. Singh
- IPO
- 1965
- Employees
- 11,000
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $10.61B
- P/E
- 44.18
- P/S
- 3.66
- P/B
- 1.48
- EV/EBITDA
- 16.93
- Div Yield
- 0.29%
Profitability
- Gross Margin
- 51.44%
- Op Margin
- 12.41%
- Net Margin
- 8.30%
- ROE
- 3.28%
- ROIC
- 2.89%
Growth & Income
- Revenue
- $2.86B · 3.67%
- Net Income
- $241.68M · -18.31%
- EPS
- $2.08 · -13.69%
- Op Income
- $356.63M
- FCF YoY
- -6.17%
Performance & Tape
- 52W High
- $118.30
- 52W Low
- $81.22
- 50D MA
- $90.17
- 200D MA
- $94.44
- Beta
- 1.05
- Avg Volume
- 1.18M
Get TickerSpark's AI analysis on RVTY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 7, 26 | MICHAS ALEXIS P | other | 1,467 |
| May 7, 26 | MICHAS ALEXIS P | other | 1,217 |
| May 7, 26 | Vandebroek Sophie V. | other | 1,265 |
| May 7, 26 | Vandebroek Sophie V. | other | 1,015 |
| May 7, 26 | Klobuchar Michael A | other | 1,265 |
| May 7, 26 | Klobuchar Michael A | other | 1,015 |
| May 7, 26 | Witney Frank | other | 1,265 |
| May 7, 26 | Witney Frank | other | 1,015 |
| May 7, 26 | Chapin Samuel R. | other | 1,265 |
| May 7, 26 | Chapin Samuel R. | other | 1,015 |
Our RVTY Coverage
View all →
Revvity, Inc. (RVTY) rises on Q1 beat and deeper margin read
Revvity, Inc. (RVTY) rises after a clean Q1 earnings beat, but the real story is in the details: stronger-than-expected margins, steady organic growth, and a guidance reset tied to a strategic China exit rather than core business weakness. Here’s what the numbers and outlook really mean.
Revvity (RVTY): Recovery Story With Software Upside
Revvity is a balanced life sciences and diagnostics operator with improving earnings, solid cash flow, and a growing software mix. The stock looks more like a recovery rerating than a breakout, but valuation is reasonable if forward EPS delivers.
Revvity, Inc. (RVTY) rises on earnings beats
Revvity, Inc. (RVTY) rises 7.0% after reporting earnings beats, as investors react positively to stronger-than-expected results and improved outlook signals.
Want a deeper read on RVTY?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.